Gilead Sciences Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Gilead Sciences Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Gilead Sciences Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Gilead Sciences Inc. is GILD:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Gilead Sciences Inc. has its primary listing on NASDAQ. You can trade Gilead Sciences Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Gilead Sciences Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Gilead Sciences Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Gilead Sciences Inc..